Michael D. Jain

机构：Moffitt Cancer Center · ORCID：0000-0002-7789-1257

发表论文 458 篇 · 总被引 8396 次 · h-index 45

代表论文

• Safety and Efficacy of Tumor-Infiltrating Lymphocyte Therapy with Reduced-Dose Lymphodepleting Conditioning in High-Risk Metastatic Melanoma Patients (2025 · Transplantation and Cellular Therapy · 被引 6)
• Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disorders (2026 · Nature Reviews Clinical Oncology · 被引 3)
• Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis (2026 · Blood Advances)
• A novel severe toxicity-free, and progression-free survival endpoint predicts outcomes after CD19 chimeric antigen receptor-T cell therapy in large B-cell lymphoma (2026 · Bone Marrow Transplantation)
• KITE-753: A phase 2 study of an autologous anti-CD19/CD20 CAR T-cell therapy in CAR-naive patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). (2026 · Journal of Clinical Oncology)
• Cladribine/cyclophosphamide lymphodepletion efficacy and toxicity in CD19 CAR-T therapy for B-ALL. (2026 · Journal of Clinical Oncology)